Skip to main content
Fig. 2 | Journal of Ovarian Research

Fig. 2

From: The cost-effectiveness analysis of maintenance olaparib plus Bevacizumab in patients with advanced ovarian cancer: based on the final survival results from PAOLA-1 trial

Fig. 2

The cost-effectiveness acceptability curves for olaparib plus bevacizumab strategy compared to bevacizumab strategy in the overall patients (A), Patients with HRD tumors (B), Patients with a tumor BRCA mutation (C), and Patients with HRD tumors without a BRCA mutation (D). Abbreviation: QALY, quality-adjusted life-year.

Back to article page

Journal of Ovarian Research

ISSN: 1757-2215

Contact us